An Open-Label Positron Emission Tomography (PET) Study Using 2 [18F] F A85380 to Determine alpha4beta2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-Fertile Female (Non-Nicotine Users) Healthy Volunteers

Trial Profile

An Open-Label Positron Emission Tomography (PET) Study Using 2 [18F] F A85380 to Determine alpha4beta2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-Fertile Female (Non-Nicotine Users) Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs AZD 1446 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Sep 2009 Actual end date (Aug 2009), actual number of patients (11) added as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top